Departamento de Fisiología, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
Br J Pharmacol. 2009 Aug;157(8):1463-73. doi: 10.1111/j.1476-5381.2009.00314.x. Epub 2009 Jun 25.
As adenosine 5'-triphosphate (ATP) is one of the inhibitory mediators of the bladder outflow region, this study investigates the possible release of ATP or related purines in response to electrical field stimulation (EFS) and the purinoceptor(s) involved in nerve-mediated relaxations of the pig urinary bladder neck.
Urothelium-denuded and intact phenylephrine-precontracted strips were mounted in organ baths containing physiological saline solution at 37 degrees C and gassed with 95% O(2) and 5% CO2 for isometric force recordings.
EFS, in the presence of atropine, guanethidine and N(G)-nitro-L-arginine, and exogenous purines, produced frequency- and concentration-dependent relaxations respectively. Adenosine 5'-diphosphate (ADP) and adenosine were more potent than ATP in producing relaxation, while uridine 5'-triphosphate, uridine 5'-diphosphate and alpha,beta-methylene ATP were less effective. The non-selective P2 antagonist suramin, and the P2Y(1) and P1 receptor blockers 2'-deoxy-N6-methyladenosine 3',5'-bisphosphate tetrasodium and 8-(p-sulphophenyl)theophylline, respectively, inhibited the responses to EFS and ATP. The P1 agonist's potency was: 5'-N-ethylcarboxamidoadenosine (NECA)>4-2[[6-amino-9-(N-ethyl-b-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzene propanoic acid hydrochloride>2-chloro-N(6)-cyclopentyladenosine>-2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-b-D-ribofuranuronamide = adenosine. 4-(-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl) phenol, an A(2A) antagonist, reduced the relaxations to EFS, adenosine and NECA. In urothelium-intact samples, relaxations to EFS and purines were smaller than in urothelium-denuded preparations. Neuronal voltage-gated Na(+) channels blockade failed to modify ATP relaxations. At basal tension, EFS- and ATP-induced contractions were resistant to desensitization or blockade of P2X(1) and P2X(3) receptors.
ATP is involved in the non-adrenergic, non-cholinergic, non-nitrergic inhibitory neurotransmission in the pig bladder neck, producing relaxation largely through muscle A(2A) receptors after breakdown to adenosine, and P2Y(1) receptors after breakdown to ADP. Antagonists of these receptors may be useful for urinary incontinence treatment produced by intrinsic sphincteric deficiency.
由于三磷酸腺苷(ATP)是膀胱流出区域的抑制性介质之一,本研究旨在探讨电刺激(EFS)下ATP 或相关嘌呤的可能释放,以及涉及猪膀胱颈部神经介导松弛的嘌呤受体。
将去尿路上皮和预先用苯肾上腺素收缩的条带安装在含有生理盐水的器官浴中,在 37°C 下进行,并用 95%氧气和 5%二氧化碳进行气体交换,进行等长力记录。
在阿托品、胍乙啶和 N(G)-硝基-L-精氨酸存在的情况下,EFS 以及外源性嘌呤,分别产生频率和浓度依赖性的松弛。二磷酸腺苷(ADP)和腺苷比 ATP 更能产生松弛作用,而尿苷 5'-三磷酸(UTP)、尿苷 5'-二磷酸(UDP)和α,β-亚甲基 ATP 的效果则较差。非选择性 P2 拮抗剂苏拉明,以及 P2Y(1)和 P1 受体阻滞剂 2'-脱氧-N6-甲基腺苷 3',5'-双磷酸四钠盐和 8-(对磺苯基)茶碱,分别抑制了对 EFS 和 ATP 的反应。P1 激动剂的效力为:5'-N-乙基羧酰胺腺苷(NECA)>4-2[[6-氨基-9-(N-乙基-β-D-核糖呋喃糖基氨基)-9H-嘌呤-2-基]氨基]乙基]苯丙酸盐酸盐>2-氯-N(6)-环戊基腺苷>-2-氯-6-[[(3-碘苄基)氨基]-9H-嘌呤-9-基]-1-去氧-N-甲基-β-D-核糖呋喃糖基酰胺=腺苷。4-([7-氨基-2-(2-呋喃基)[1,2,4]三唑并[2,3-a][1,3,5]三嗪-5-基氨基]乙基)苯酚,一种 A(2A)拮抗剂,可减轻 EFS、腺苷和 NECA 引起的松弛反应。在完整尿路上皮的样本中,EFS 和嘌呤引起的松弛反应小于去尿路上皮的样本。神经元电压门控 Na(+)通道阻断未能改变 ATP 松弛作用。在基础张力下,EFS 和 ATP 诱导的收缩对 P2X(1)和 P2X(3)受体的脱敏或阻断无反应。
ATP 参与了猪膀胱颈部的非肾上腺素能、非胆碱能、非氮能抑制性神经传递,在分解为腺苷后主要通过肌肉 A(2A)受体,在分解为 ADP 后通过 P2Y(1)受体产生松弛作用。这些受体的拮抗剂可能对由内在括约肌缺陷引起的尿失禁治疗有用。